MEIP Stock Overview
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MEI Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.25 |
| 52 Week High | US$7.97 |
| 52 Week Low | US$3.20 |
| Beta | 0.64 |
| 1 Month Change | -12.63% |
| 3 Month Change | -31.29% |
| 1 Year Change | -32.57% |
| 3 Year Change | -95.25% |
| 5 Year Change | -94.72% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)
Feb 17
Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)
Dec 30Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)
Nov 19We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely
May 18Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022
Mar 26Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts
Feb 12MEI Pharma: Another PI3K Delta Progressing To The FDA
Feb 01Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates
Dec 02We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate
Nov 04MEI Pharma EPS misses by $0.12, misses on revenue
May 06MEI Pharma promotes Richard Ghalie to chief medical officer
Apr 30MEI Pharma shares rise 4% as Wells Fargo says voruciclib undervalued
Apr 26The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding
Feb 25New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)
Feb 11
MEI Pharma EPS beats by $0.01, beats on revenue
Feb 04Shareholder Returns
| MEIP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.5% | -4.7% | -3.7% |
| 1Y | -32.6% | -2.7% | 20.2% |
Return vs Industry: MEIP underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: MEIP underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| MEIP volatility | |
|---|---|
| MEIP Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MEIP's share price has been volatile over the past 3 months.
Volatility Over Time: MEIP's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 46 | David Urso | www.meipharma.com |
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer.
MEI Pharma, Inc. Fundamentals Summary
| MEIP fundamental statistics | |
|---|---|
| Market cap | US$21.65m |
| Earnings (TTM) | US$19.84m |
| Revenue (TTM) | US$72.65m |
1.1x
P/E Ratio0.3x
P/S RatioIs MEIP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEIP income statement (TTM) | |
|---|---|
| Revenue | US$72.65m |
| Cost of Revenue | -US$25.96m |
| Gross Profit | US$98.61m |
| Other Expenses | US$78.76m |
| Earnings | US$19.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.98 |
| Gross Margin | 135.73% |
| Net Profit Margin | 27.32% |
| Debt/Equity Ratio | 0% |
How did MEIP perform over the long term?
See historical performance and comparison